<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Secretory leukocyte <z:chebi fb="0" ids="37670">protease inhibitor</z:chebi> (SLPI) is a serine <z:chebi fb="0" ids="37670">protease inhibitor</z:chebi> that was related to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> dissemination on several types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is not known the effect of SLPI on mammary and <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to examine the effect of SLPI on mammary and <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> growth </plain></SENT>
<SENT sid="3" pm="."><plain>The effect of SLPI was tested on in vitro cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and in vivo <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> experiments </plain></SENT>
<SENT sid="4" pm="."><plain>SLPI over-expressing human and murine mammary and <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cells were generated by gene transfection </plain></SENT>
<SENT sid="5" pm="."><plain>The administration of murine <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> cells over-expressing high levels of SLPI did not develop <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice </plain></SENT>
<SENT sid="6" pm="."><plain>On the contrary, the administration of murine <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cells over-expressing SLPI, developed faster <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> than control cells </plain></SENT>
<SENT sid="7" pm="."><plain>Intratumoral, but not intraperitoneal administration of SLPI, delayed the growth of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and increased the survival of mammary but not <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> bearing mice </plain></SENT>
<SENT sid="8" pm="."><plain>In vitro culture of <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> cell lines treated with SLPI, and SLPI producer clones were more prone to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> than control cells, mainly under serum deprivation culture conditions </plain></SENT>
<SENT sid="9" pm="."><plain>Herein we demonstrated that SLPI induces the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> cells in vitro and decreases the mammary but not <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> growth in vivo </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, SLPI may be a new potential therapeutic tool for certain <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, such as <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumors</z:e> </plain></SENT>
</text></document>